Research
Hormonal
GLP-1 receptor agonists (Liraglutide, Semaglutide) are effective and safe for treating obesity in children and adolescents, with FDA approval for Liraglutide in this population.
For children and adolescents with obesity, Liraglutide is an FDA-approved option. It helps reduce weight (avg 2.74 kg in trials) and improves HbA1c. Side effects are generally mild GI symptoms or minor hypoglycemia. It should be used alongside diet and exercise.
ModerateSupportsMEDIUM confidence
Recently, the US Food and Drug Administration (FDA) approved the use of the GLP1 agonist (Liraglutide) for children... GLP-1 agonist therapy reduced weight mainly in children with obesity (2.74 kg reduction) when compared to obese children with T2DM (0.97% reduction).
Why this rating
Based on randomized controlled trials cited, but fewer studies than adult population.
Source
Use of GLP-1 analogs in the treatment of obesity: an integrative and systematic review
Giulia Biagi Furlan et al. · International Journal of Nutrology · 2023
DOI 10.54448/ijn23105
Meta-analysis · 40 studiesCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (specifically semaglutide 2.4 mg/week and liraglutide 3.0 mg/day) produce significant weight loss in adults with obesity (BMI ≥27 or ≥30) when combined with lifestyle modifications, outperforming placebo and many other pharmacotherapies.Good
- GLP-1 receptor agonists (exenatide, liraglutide) are effective for weight loss in patients with schizophrenia who are gaining weight due to antipsychotic medications (clozapine/olanzapine).Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →